Evolent Health, Inc (EVH) Insider Sells $40,474.76 in Stock

Evolent Health, Inc (NYSE:EVH) insider Nicholas Mcgrane sold 1,667 shares of Evolent Health stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $24.28, for a total transaction of $40,474.76. Following the sale, the insider now directly owns 132,047 shares of the company’s stock, valued at $3,206,101.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Nicholas Mcgrane also recently made the following trade(s):

  • On Monday, June 12th, Nicholas Mcgrane sold 1,667 shares of Evolent Health stock. The stock was sold at an average price of $24.58, for a total transaction of $40,974.86.
  • On Wednesday, June 7th, Nicholas Mcgrane sold 10,495 shares of Evolent Health stock. The stock was sold at an average price of $26.95, for a total transaction of $282,840.25.
  • On Friday, May 19th, Nicholas Mcgrane sold 47,508 shares of Evolent Health stock. The stock was sold at an average price of $24.30, for a total transaction of $1,154,444.40.
  • On Wednesday, April 19th, Nicholas Mcgrane sold 1,667 shares of Evolent Health stock. The stock was sold at an average price of $22.52, for a total transaction of $37,540.84.
  • On Friday, March 24th, Nicholas Mcgrane sold 7,034 shares of Evolent Health stock. The stock was sold at an average price of $22.50, for a total transaction of $158,265.00.

Evolent Health, Inc (NYSE:EVH) opened at 26.40 on Friday. The stock’s market cap is $1.52 billion. The firm has a 50 day moving average of $24.43 and a 200-day moving average of $20.48. Evolent Health, Inc has a 52-week low of $14.50 and a 52-week high of $27.50.

Evolent Health (NYSE:EVH) last announced its earnings results on Tuesday, May 9th. The technology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $104.38 million. During the same period in the prior year, the company posted ($0.16) EPS. The company’s revenue was up 116.2% compared to the same quarter last year. Equities analysts anticipate that Evolent Health, Inc will post ($0.41) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

ILLEGAL ACTIVITY WARNING: “Evolent Health, Inc (EVH) Insider Sells $40,474.76 in Stock” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2017/06/17/insider-selling-evolent-health-inc-evh-insider-sells-40474-76-in-stock-updated-updated-updated.html.

EVH has been the topic of a number of analyst reports. Robert W. Baird initiated coverage on shares of Evolent Health in a research report on Thursday, June 1st. They issued an “outperform” rating and a $30.00 target price on the stock. CIBC initiated coverage on shares of Evolent Health in a research report on Tuesday, March 14th. They issued an “outperform” rating on the stock. Zacks Investment Research cut shares of Evolent Health from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Cantor Fitzgerald reiterated a “buy” rating and issued a $26.00 target price on shares of Evolent Health in a research report on Wednesday, March 1st. Finally, Goldman Sachs Group, Inc. (The) upgraded shares of Evolent Health from a “buy” rating to a “conviction-buy” rating and set a $30.00 target price on the stock in a research report on Wednesday, March 8th. One equities research analyst has rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $28.40.

Large investors have recently made changes to their positions in the stock. US Bancorp DE increased its position in Evolent Health by 0.3% in the first quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock valued at $126,000 after buying an additional 19 shares in the last quarter. Point72 Asia Hong Kong Ltd bought a new position in Evolent Health during the first quarter valued at approximately $126,000. Bank of Montreal Can increased its position in Evolent Health by 4,249.7% in the first quarter. Bank of Montreal Can now owns 6,220 shares of the technology company’s stock valued at $138,000 after buying an additional 6,077 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Evolent Health by 286.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,744 shares of the technology company’s stock valued at $150,000 after buying an additional 5,000 shares in the last quarter. Finally, IPG Investment Advisors LLC bought a new position in Evolent Health during the first quarter valued at approximately $206,000. 73.66% of the stock is currently owned by institutional investors and hedge funds.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply